Literature DB >> 16285895

Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma.

Shanjin Cao1, Zhaoying Xiang, Xiaojing Ma.   

Abstract

Interleukin-12 (IL-12) is a critical cytokine representing the link between the cellular and humoral branches of host immune defense apparatus. IL-12-induced cytotoxic lymphocyte (CTL) development is a central mechanism in immune responses against intracellular infectious agents as well as malignant growth. However, the molecular basis of tumor-specific CTL responses mediated by IL-12 remains poorly defined. In this study, we addressed this issue in a comprehensive manner to probe into IL-12-induced anti-tumor responses by global gene expression profiling of mRNA expression in CD8(+) T cells in a transplantable syngeneic mouse mammary carcinoma model treated or not with recombinant IL-12. A strong tumor regression was induced by the IL-12 treatment. An introspection of differential gene expression at an early stage of the IL-12-initiated CTL activation reveals interesting genes and molecular pathways that may account for the marked tumor regression, and is likely to provide a rich source of potential targets for further research and development of effective therapeutic modalities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16285895      PMCID: PMC2965067     

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  84 in total

1.  Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells.

Authors:  J H Xin; A Cowie; P Lachance; J A Hassell
Journal:  Genes Dev       Date:  1992-03       Impact factor: 11.361

Review 2.  Tumor antigens recognized by T cells.

Authors:  T Boon; P G Coulie; B Van den Eynde
Journal:  Immunol Today       Date:  1997-06

Review 3.  Structure-function relationships of the PEA3 group of Ets-related transcription factors.

Authors:  Y de Launoit; J L Baert; A Chotteau; D Monte; P A Defossez; L Coutte; H Pelczar; F Leenders
Journal:  Biochem Mol Med       Date:  1997-08

4.  Molecular cloning and characterization of a novel type of regulatory protein (GDI) for smg p25A, a ras p21-like GTP-binding protein.

Authors:  Y Matsui; A Kikuchi; S Araki; Y Hata; J Kondo; Y Teranishi; Y Takai
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

5.  Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors.

Authors:  F Rilke; M I Colnaghi; N Cascinelli; S Andreola; M T Baldini; R Bufalino; G Della Porta; S Ménard; M A Pierotti; A Testori
Journal:  Int J Cancer       Date:  1991-08-19       Impact factor: 7.396

6.  Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12.

Authors:  F Cavallo; P Signorelli; M Giovarelli; P Musiani; A Modesti; M J Brunda; M P Colombo; G Forni
Journal:  J Natl Cancer Inst       Date:  1997-07-16       Impact factor: 13.506

7.  Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.

Authors:  J Guo; B Wang; M Zhang; T Chen; Y Yu; E Regulier; H E Homann; Z Qin; D W Ju; X Cao
Journal:  Gene Ther       Date:  2002-06       Impact factor: 5.250

Review 8.  T-cell responses at the host: tumour interface.

Authors:  R A Robins
Journal:  Biochim Biophys Acta       Date:  1986-12-17

9.  TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma.

Authors:  P Nanni; C de Giovanni; P L Lollini; G Nicoletti; G Prodi
Journal:  Clin Exp Metastasis       Date:  1983 Oct-Dec       Impact factor: 5.150

Review 10.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.